Atantares
Smart biochips powered by AI to advance precision diagnostics and medicine.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | Series A | |
| Total Funding | 000k | ||
Related Content
Atantares is a biotechnology firm that emerged from research conducted at the Massachusetts Institute of Technology and Harvard University, specializing in the development of therapeutic interventions for complex diseases.
The company was co-founded by Dr. M. Amin Arnaout, Dr. Shaker A. Mousa, and Dr. Joseph V. Bonventre. Dr. Arnaout, a physician-scientist, serves as the Chief of Nephrology at Massachusetts General Hospital and is a Professor of Medicine at Harvard Medical School, bringing extensive experience in molecular and cell biology to the company. Dr. Mousa holds the position of Professor of Pharmacology and serves as the Executive Vice President and Chairman of the Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences. Dr. Bonventre is the Chief of the Division of Renal Medicine at Brigham and Women's Hospital and a Professor of Medicine at Harvard Medical School. The collective expertise of the founders in nephrology, pharmacology, and renal medicine forms the scientific foundation of the company's research and development efforts.
Atantares directs its focus on creating treatments for conditions within hematology, cardiology, neurology, and oncology. The firm's primary business involves advancing its pipeline of drug candidates through preclinical and clinical trials. A key asset in their portfolio is AT-101, a small molecule integrin inhibitor designed to target α4β1 and α4β7 integrins. This compound has been investigated for its potential in treating sickle cell disease by preventing the adhesion of blood cells to the vessel walls, a process that contributes to vaso-occlusive crises. The company operates within the biopharmaceutical market, targeting collaborations with larger pharmaceutical companies for late-stage development and commercialization, a common strategy for research-intensive biotech startups.
Keywords: biotechnology, drug development, integrin inhibitors, sickle cell disease, hematology, cardiology, neurology, oncology, biopharmaceutical, clinical trials